0001209191-24-000809.txt : 20240104 0001209191-24-000809.hdr.sgml : 20240104 20240104164230 ACCESSION NUMBER: 0001209191-24-000809 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240102 FILED AS OF DATE: 20240104 DATE AS OF CHANGE: 20240104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nagendran Sukumar CENTRAL INDEX KEY: 0001665124 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 24512716 MAIL ADDRESS: STREET 1: C/O AVEXIS, INC., 2275 HALF DAY ROAD STREET 2: SUITE 160 CITY: BANNOCKBURN STATE: IL ZIP: 60015 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-01-02 0 0001806310 Taysha Gene Therapies, Inc. TSHA 0001665124 Nagendran Sukumar C/O TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE, SUITE 1430 DALLAS TX 75247 1 1 0 0 President and Head of R&D 0 Common Stock 2024-01-02 4 A 0 863617 0.00 A 897843 D Employee Stock Option (right to buy) 1.71 2024-01-02 4 A 0 863617 0.00 A 2034-01-02 Common Stock 863617 863617 D Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. 25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ Kamran Alam, Attorney-in-Fact 2024-01-04